Q&A

General

Could you please give our viewers a brief history of your company.

Modified

26.Oct 18

In brief, SCO-101 was originally developed by the Danish biotech company Neurosearch A/S to treat patients with Sickle Cell Anemia, which is a non-cancer hemoglobin disease. However, they were not satisfied with their first results and further development was stopped.

Neurosearch A/S was acquired by Saniona AB, which is on First North in Stockholm. At that time Nils Brünner, CEO of Scandion Oncology was CEO for WntResearch and the CFO in WntResearch, Thomas Feldthus, was one of the founders of Saniona. He introduced Nils Brünner to the CEO of Saniona, Jørgen Drejer, and several conversations about drug development were initiated. At the same time, Nils Brünner together with Associate Professor Jan Stenvang, at the University of Copenhagen, established a novel drug screening platform consisting of pairs of drug sensitive and drug resistant cancer cell lines. Nils Brünner and CSO Jan Stenvang obtained SCO-101 from Saniona and tested it in the screenings platform. The studies showed that SCO-101 by itself has no anti-cancer effects but when combined with standard cancer treatments in drug resistant cancer cell lines, SCO-101 blocked important resistance mechanisms rendering the cancer cells sensitive to treatment again. SCO-101 had been tested in 92 humans already at the time of Neurosearch and is now ready for phase II in cancer. We established Scandion Oncology in May 2017 and money is currently being raised to continue the clinical development in patients with drug resistant cancer.

Could you please share with us your favorite memory and or event since you joined the company?

Modified

26.Oct 18

The day we decided to spin-out Scandion Oncology from University of Copenhagen and Saniona. It was a dream that came through for us – to establish our own company based on our own cancer research. Only by taking SCO-101 through a commercialization process, we will be able to bring our many years of research out to the benefit of cancer patients.

During your time at Scandion Oncology what has been in your eyes your greatest achievement thus far?

Modified

26.Oct 18

To discover that SCO-101 could reverse drug resistance in cancer and to identify the mechanisms of actions for this effect.

What sets your company apart from those within your industry?

Modified

26.Oct 18

As far as we are aware, we are the only company having a drug against drug resistance in cancer in clinical development. So our “X factor” is a unique and safe oral drug that targets the perhaps most important problem in today’s cancer treatment: Existing or acquired drug resistance leading to the death of millions every year.

Pre-clinical

In one of your slides that you use for presentations, it says that you have identified a non-cancer indication for SCO-101. Can you tell us more about this other indication?

Modified

26.Oct 18

It is correct that we now have preclinical data on SCO-101 and a non-cancer indication. We are presently preparing for a new patent application for this. The only information I can give right now is that this other indication could be as big as the cancer indication. We will initiate screening of our approximately 800 SCO-101 analogs in order to select a candidate for this indication.

Clinical

When do you expect that breast cancer patients can receive your drug?

Modified

26.Oct 18

We plan to initiate in late 2019 the clinical phase II study with metastatic breast cancer patients and docetaxel/paclitaxel resistant disease. Please contact Nils Brünner CEO (nb@scandiononcology.com) for further information.

Do you have any plans to initiate clinical studies with SCO-101 in other indications than breast cancer?

Modified

26.Oct 18

Yes, we plan to initiate clinical studies also in colorectal cancer and most probably also in pancreatic cancer but we will need more resources in order to do this.

Jag undrar lite om era fas 1 studier, då jag inte hittar så mycket information om dessa. Hur kommer det sig att det gjorts hela fyra fas 1 studier? Då man oftast vill söka effekt i fas 2.

Modified

13.Nov 18

When Scandion Oncology was established in 2017 we received all documentation on the four Phase I clinical trials from Saniona. These trials were conducted around 2002 and the data were not published. We plan to include some of these data in our coming publications. All studies were performed in healthy volunteers. The four studies comprised

  1. Single doses
  2. Escalation doses
  3. Females and males
  4. Food interaction (since SCO-101 is delivered in a capsule)

The original plans for SCO-101 were to use it to treat a disease named sickle cell anemia. This is an inherited blood disease where the erythrocytes (red blood cells) have a sickle shape and they are more fragile. However, SCO-101 caused a slight and reversible increase in serum bilirubin and was therefore found unsuitable for treatment of a disease that results in increased serum bilirubin by itself.

This I fortunately not considered a problem when combining with anti-cancer treatment.

Financials

Is it correct that we can now pre-invest in Scandion Oncology?

Modified

26.Oct 18

We have just finalized the presubscription period, which went extremely well. From October 4, it will be possible to subscribe to Scandion Oncology shares at Spotlight. Please contact Nils Brünner, CEO (NB@ScandionOncology.com) for further information.

When does Scandion Oncology plan to have investor meetings in 2018?

Modified

26.Oct 18

There will be investor meetings at

Investerarträff Copenhagen, October 4, 2018

From 17:30-19:30

Radisson Royal Copenhagen,
Hammerichsgade 1,
1611 København V

Sedermeradagen Göteborg, October 11, 2018

From 11:00-18:00

Elite Park Avenue Hotel,
Kungsportsavenyen 36,
411 36 Göteborg

Investerarträff Stockholm, October 12, 2018

From 11:30-13:00

Scandic Klara,
Slöjdgatan 7,
111 57 Stockholm

How many staff do you have currently on the team

Modified

26.Oct 18

We have a CEO (Nils Brünner), a CSO (Jan Stenvang), a CMO (Peter Michael Vestlev) and a CFO (Carit Andersen).

Do any of the staff and or management team hold any shares within the company?

Modified

26.Oct 18

We all do and we have all invested in the Scandion Oncology.

What are Scandion Oncology´s medium to long-term goals and have these goals been consistent for some time?

Modified

26.Oct 18

To successfully pass clinical phase II with SCO-101, thereby obtaining clinical proof-of-concept, and then find a partner or a licensee. Next step will be to take our second drug candidate, SCO-201 through preclinical and clinical development.

Presentation

Media element